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Abstract
Crush syndrome is characterized by ischemia/reperfusion injury (IRI). The
protective effect of nitrite on experimentally induced IRI has been demon-
strated in the heart, kidney, liver, and skeletal muscle. IRI in tissues and sys-
temic organs occurs due to the massive generation of reactive oxygen species
and subsequent systemic inflammation. Therefore, ischemic pre and postcon-
ditioning are performed in clinical practice. Intravenous administration of
nitrite inhibits IRI through nitric oxide-mediated mechanisms. In this paper,
we discuss the utility of nitrite as a pharmacological postconditioning agent in
the treatment of crush syndrome.
Introduction
Crush syndrome (CS) develops due to the sudden
decompression of limb muscles (reperfusion injury) fol-
lowing prolonged compression (ischemia) (Murata et al.
2011). Beneficial effects of nitrite in the treatment of
ischemia/reperfusion injury (IRI) in the cardiac muscle
have been reported (Bryan et al. 2007; Gonzalez et al.
2008; Carlstr€om et al. 2011); however, its effects in the
skeletal muscle are not well-known. Murata et al.
(2012) have demonstrated the therapeutic efficiency of
nitrite using animal models of acute CS. They reported
that conventional saline infusion and bicarbonate
hydration therapies are associated with survival rates of
approximately 40 and 80%, respectively, at 48 h after
reperfusion, as opposed to 20% survival in untreated
CS control animals (Murata et al. 2012, 2017b). How-
ever, an intravenous injection of nitrite, immediately
before reperfusion, raised the survival rate above 60%.
Furthermore, rats treated with continuous nitrite infu-
sion for 3 h, following reperfusion with saline for
hypovolemia correction, exhibited 100% survival (Mur-
ata et al. 2012, 2013, 2017b) (Fig. 1). They also showed
that nitrite levels in the skeletal muscles decreased due
to prolonged ischemia. Similar results have been
reported for ischemia in the heart and liver tissues in
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animal models of IRI. Nitrite is an on-demand nitric
oxide (NO) donor, as well as a nitrosating agent serv-
ing as a signaling molecule and a gene regulator, espe-
cially in hypoxic tissues, by posttranslational protein
modification at heme and sulfhydryl sites (Bryan et al.
2005; Kobayashi et al. 2015). Therefore, increasing
endogenous and exogenous nitrite levels seems benefi-
cial for the treatment of CS.
IRI is Responsible for the
Development of CS
An important characteristic feature of CS is the systemic
inflammatory response following reperfusion to ischemic
local skeletal muscles (Murata et al. 2013). Individuals
trapped under heavy debris due to building collapse or
bombing may have their extremities compressed; such
individuals may not experience pain once these body
parts have become numb due to lack of blood supply.
However, if the crushing pressure is suddenly removed,
oxygenated blood rushes into these ischemic tissues
(reperfusion), resulting in further damage. This is fol-
lowed by rhabdomyolysis and the release of proinflamma-
tory mediators to the lungs and kidneys, leading to
systemic inflammation. This devastating cascade of events
results in life-threatening conditions, such as circulatory
shock, renal failure, and acute respiratory distress syn-
drome (Sever et al. 2002).
Ischemic Duration of Skeletal
Muscles is Critical for Preventing
Mortality Following Reperfusion
Mortality rates associated with CS vary depending on the
ischemic duration of skeletal muscles. Ischemic duration
directly correlates with the extent of tissue damage.
Almost complete survival may be expected if the tissue
damage is less; however, ATP depletion and osmotic swel-
ling make the cells more susceptible to cell disruption fol-
lowing reperfusion (Ferdinandy et al. 2007). A prolonged
ischemic duration leads to a no-reflow phenomenon char-
acterized by microvascular occlusion in the infarct core.
The only treatment to ensure survival is to amputate the
necrotic limbs. The identification of ischemic duration is
critical to decide the treatment approach. Murata et al.
(2011) reported that 5 h of tourniquet-induced skeletal
muscle ischemia in rats resulted in 100% acute phase
mortality within 24 h after reperfusion; however, mortal-
ity dropped to 0 and 10% with ischemic durations of 4
and 6 h, respectively. No systemic release of inflammatory
mediators was observed with crush periods less than 4 h
(less tissue damage) and greater than 6 h (no-reflow phe-
nomenon). The microvasculature is completely occluded
following ischemic durations of 6 h or more (Blaisdell
2002). Although the critical ischemic period differs with
the organ, animal species, and experimental device used
for inducing ischemia, a crush period of 5 h in rats effec-
tively simulates lethal CS with severe rhabdomyolysis and
subsequent acute circulatory, respiratory, and renal fail-
ures (Murata et al. 2011).
Nitrite is Depleted in Ischemic Tissues
Tissue nitrite levels decrease after persistent ischemia in
the liver, heart, and skeletal muscles (McNulty et al.
2008; Raat et al. 2009a), indicating nitrite depletion
during ischemia. Tissue nitrite serves as an NO reser-
voir and NO donor under hypoxic and acidic condi-
tions in the heart and skeletal muscles. The released
NO and NO+ then drive various signaling pathways
through the activation of soluble guanylate cyclase and/
or cGMP-independent transnitrosation (Tiravanti et al.
2004), and plays an important role in protecting the
cells and tissues during ischemia. It induces hypoxic
vasodilation, reduces oxygen consumption (by inhibiting
mitochondrial complexes I, IV, and V), opens KATP
channels, prevents cytochrome c release, and blocks the
opening of mitochondrial permeability transition pore
(mPTP). Consistent with these effects, orally, intraperi-
toneally, or intravenously administered nitrite attenuates
IRI-induced damage to the heart, brain, kidney, and
liver. Mice fed a diet deficient in nitrate and nitrite for
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Figure 1. Survival rates associated with different treatments in a
rat model of crush syndrome (CS). Data published by Murata
et al.(2012, 2013, 2017a,b) are reproduced after modification;
sham group, surgically treated rats without CS (○: n = 10); CS
group, untreated rats with CS (●:n = 29); saline group, CS rats
treated with saline infusion (30 mL/kg/h for 3 h) for volume
expansion following reperfusion (M:n = 10); nitrite i.v. group, CS
rats treated with 200 lmol/kg nitrite injection (◇:n = 14);
bicarbonate with saline group, CS rats treated with bicarbonate
admixed saline infusion (30 mL/kg/h for 3 h)(▲: n = 10); 200 lmol/
L nitrite with saline group, CS rats treated with 200 lmol/kg nitrite
in saline infusion (30 mL/kg/h for 3 h) (◆:n = 10) * P < 0.05 vs.
sham, # P < 0.05 vs. CS, + P < 0.05 vs. saline, by log-rank test.
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7 days exhibit diminished plasma and heart levels of
nitrite and show severe myocardial infarction following
experimentally induced IRI. However, nitrite supple-
mentation attenuated myocardial infarction in a dose-
dependent manner (Bryan et al. 2007). This suggests
that endogenous nitrite confers tolerance to ischemia.
Therefore, prophylactic nitrite administration may be
effective in protecting the tissues from IRI.
Ischemic preconditioning involves exposing the tissues
to several brief intervals of sublethal ischemia followed by
reperfusion to induce low levels of reactive oxygen species
(ROS). This activates the reperfusion injury salvage kinase
(RISK) pathway, which involves Akt/endothelial NO syn-
thase (eNOS) activation and subsequent NO-mediated
cytoprotective signaling (Kim et al. 2004; Ferdinandy
et al. 2007) (Fig. 2). However, due to the unpredictable
nature of the onset of crush injury, pharmacological pre-
conditioning with NO is impractical. Nevertheless, it may
be useful as an onsite postconditioning agent immediately
before reperfusion.
I/R injury
↓
ROS
↓
Ca2+
↓
mPTP 
opening
↓
Necrosis (rhabdomyolysis)/apoptosis
↓
↓
Hyperkalemia (cardiac arrest)
Systemic release of proinflammatory mediators
(TNF-α, Mb, et al.)
↓
NADPH oxidase and XO-mediated ROS production
Systemic inflammation with leukocyte recruitment
↓
Hypovolemic shock, ARDS, acute renal failure, DIC
Skeletal muscle
eNOS← pre/post-conditioning
(RISK pathway)
S-nitrosation of complex I 
in mitochondria
reductase-mediated nitrite reduction
(XO, ALDH2 et al.)
Vascular endothelium(lung, kidney)
hypoxic nitrite reduction
(deoxy Hb, deoxy Mb, et al.)
NO/ NO+
NO/NO+ nitrite
nitrite
cGMP-dependent and -independent mechanism
Blocking mPTP opening 
via cGMP/PKG signaling
S-nitrosation of L type Ca 
channel and SERCa 2a
Figure 2. Schematic representation of IRI and RISK pathways linked to NO-mediated cytoprotection. Pre and postconditioning phosphorylate
PI3K-Akt, and MEK-1/2-ERK-1/2 cascades, which are also associated with phosphorylation of eNOS (RISK pathway) (Liem et al. 2007).
Pharmacological postconditioning with nitrite shares cGMP-dependent and independent (nitrosation and nitrosylation) pathways with the RISK
pathway (Liem et al. 2007). The major mediators of post-IRI are ROS production, dysregulated intracellular Ca2+ overload, and mPTP opening.
Nitrite inhibits ROS generation by nitrosation of complex I in the mitochondrial respiratory chain. Nitrite inhibits cytosolic Ca2+ overload by
nitrosation of L-type Ca2+ channels (inhibiting Ca2+ release) and SERCA2a (activating Ca2+ uptake) (Sun et al. 2007). Nitrite also inhibits mPTP
opening by phosphorylating serine/threonine residues of mitochondrial proteins by activating cGMP/PKG signaling (Kim et al. 2004). Then, the
IRI in skeletal muscle enters the second stage, where systemic inflammation occurs in the vascular endothelium of vital organs including kidney
and lung. Although nitrite remarkably reduces rhabdomyolysis and systemic release of proinflammatory mediators by decreasing cell
vulnerability to reperfusion, abnormal interactions of leukocytes with systemic vascular endothelium are inhibited by nitrite-derived NO/N2O3,
preventing lethal complications (hypovolemic shock, ARDS, acute renal failure, and DIC) to secondary systemic inflammation (Murata et al.
2017b). RISK pathway, reperfusion injury salvage kinase pathway; IRI, ischemia/reperfusion injury; PI3K, phosphoinositide 3-kinase; MEK-1/2,
MAPK (Mitogen-Activated Protein Kinase)/ERK (Extracellular signal-Regulated Kinases) kinase-1/2; ROS, reactive oxygen species; mPTP,
mitochondrial permeability transition pore; NO, nitric oxide; eNOS, endothelial NO synthase; ARDS, acute respiratory distress syndrome; DIC,
disseminated intravascular coagulation; XO, xanthine oxidase; TNF, tumor necrosis factor; ALDH, aldehyde dehydrogenase; Hb, hemoglobin;
Mb, myoglobin; SERCA, sarco/endoplasmic reticulum Ca²⁺-ATPase.
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Nitrite as a Pharmacological
Postconditioning Agent for the Acute
Phase Treatment of IRI
Postconditioning involves tissue exposure to brief alter-
nating periods of ischemia and reflow, applied at the
onset of reperfusion, following sustained ischemia
(Tsang et al. 2004). Postconditioning was initially
thought to attenuate IRI by gradually reintroducing
oxygen to ischemic tissues or diluting toxic metabolites
at the ischemic site; however, it was found to activate
the RISK pathway involving survival PI3K/Akt pathways
leading to NO-mediated signaling (Hausenloy et al.
2005) (Fig. 2). This has been verified by pharmacologi-
cal inhibition studies of RISK pathway components
(Tsang et al. 2004) and the measurement of the levels
and enzymatic activities of eNOS and inducible NOS
(Brunner et al. 2003; Elrod et al. 2006; West et al.
2008). Manipulation of these enzymes by knockout or
transgenic overexpression studies in IRI animal models
further highlights the role of postconditioning in CS
treatment (Ozaki et al. 2002).
Sudden oxygen rush to anoxic tissues following
reperfusion generates a large amount of ROS, particu-
larly at mitochondrial complex I (the entry point for
electrons from NADH into the respiratory chain), fol-
lowed by Ca2+ overload, mPTP opening, and cyto-
chrome c release, leading to cell necrosis/apoptosis.
Therefore, ROS generation after reperfusion could be
responsible for ischemic tissue damage and subsequent
systemic release of proinflammatory mediators, which
react with the vascular endothelium and cause multiple
organ failures (Murata et al. 2011). Nitrite protects the
hypoxic tissues from reperfusion injury by limiting ROS
generation via posttranslational S-nitrosylation of com-
plex I (at Cys39 on the ND3 subunit), which becomes
susceptible to this modification only during ischemia
(Chouchani et al. 2013). In addition, the cytoprotective
effects of nitrite may be mediated by S-nitrosylation
and S-glutathionylation of redox-sensitive cysteine resi-
dues of Ca2+ handling channels and receptors (L-type
Ca2+ channel, ryanodine receptor type 1, and sarcoen-
doplasmic reticulum Ca2+ transport ATPase) to prevent
ROS-induced oxidation and abnormal intracellular Ca2+
handling (Aracena-Parks et al. 2006; Sun et al. 2007;
Sun and Murphy 2010). Although detailed mechanisms
are not fully known, these effects attenuate the increase
in cytosolic Ca2+ during ischemia and Ca2+ overload
during reperfusion.
An intravenous infusion of nitrite confers greater
protection against IRI than a bolus intravenous injec-
tion in CS rats (Fig. 2). Systemically infused nitrite is
catalyzed to NO by aldehyde dehydrogenase 2 (Sonoda
et al. 2014), and reacts with deoxyhemoglobin to form
NO-hemoglobin (Lundberg et al. 2008). Due to the
inflammatory surge during ischemia, leukocytes abnor-
mally interact with the vascular endothelium and lead
to secondary ROS generation induced by leukocyte
NADPH oxidase and vascular xanthine oxidase (Raat
et al. 2009b). NO and its metabolites prevent this inter-
action.
Intravenous injection of dexamethasone (Murata et al.
2013) and astragaloside IV, the primary pure saponin iso-
lated from Astragalus membranaceus, have potent anti-
inflammatory and antioxidant actions, and are associated
with 100% survival rates in CS rat models (Murata et al.
2017a). Similar to nitrite, they enhance eNOS phosphory-
lation, inhibit ROS production, and aid pre and postcon-
ditioning in IRI.
Safety Concerns About Nitrite
Infusion
Murata et al. (2012) demonstrated that 200 lmol/kg of
intravenously administered nitrite has no impact on
mean arterial pressure and methemoglobin levels. In
addition, rats treated with continuous saline infusion
along with 200 lmol/kg of nitrite for 3 h after reperfu-
sion exhibited 100% survival without any hypotensive
effect or methemoglobinemia (Murata et al. 2017b). On
the other hand, Pluta et al. (2011) reported the safety
and feasibility of intravenous sodium nitrite infusion in
healthy volunteers. They showed that a dose of
20 lmol/kg/3 h leads to nitrite-limiting toxicity, includ-
ing a transient asymptomatic decrease (>15 mmHg) in
mean arterial pressures and/or an asymptomatic
increase (>5%) in methemoglobin levels in humans.
Although lower doses of nitrite need to be evaluated
for the treatment of CS, these results specify the effec-
tive lower limit of nitrite dose in the clinical treatment
of CS.
Conclusion
In addition to conventional infusion therapy for extracel-
lular fluid volume expansion and acid-base control, nitrite
infusion therapy is a promising pharmacological interven-
tion for the treatment of CS through a protective mecha-
nism involving NO-mediated signaling. Therefore, we
propose that treatment with low-cost nitrite infusion
should be clinically implemented to prevent IRI and as a
potential therapeutic agent for CS.
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